Menu
Search
|

Menu

Close
X

Histogenics Corp HSGX.OQ (NASDAQ Stock Exchange Capital Market)

0.22 USD
+0.02 (+8.25%)
As of Sep 13
Previous Close 0.21
Open 0.21
Volume 1,988,538
3m Avg Volume 1,237,625
Today’s High 0.23
Today’s Low 0.20
52 Week High 1.43
52 Week Low 0.08
Shares Outstanding (mil) 94.60
Market Capitalization (mil) 17.60
Forward P/E 1.73
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.117
FY18
-0.292
FY17
-1.004
FY16
-1.239
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
1.73
33.85
Price to Sales (TTM)
vs sector
--
7.90
Price to Book (MRQ)
vs sector
--
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
--
17.64
LT Debt to Equity (MRQ)
vs sector
--
12.61
Return on Investment (TTM)
vs sector
-25.37
12.69
Return on Equity (TTM)
vs sector
--
17.13

EXECUTIVE LEADERSHIP

Joshua Baltzell
Independent Chairman of the Board, Since 2019
Salary: --
Bonus: --
Adam Gridley
President, Director, Since 2019
Salary: $435,000.00
Bonus: $382,725.00
Donald Haut
Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Jonathan Lieber
Interim Chief Financial Officer, Since 2018
Salary: $335,325.00
Bonus: $168,365.00
David Hood
Director, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

830 Winter St
WALTHAM   MA   02451-1477

Phone: +1781.4577900

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company's product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient's own cartilage cells through a series of tissue engineering processes. The patient's cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company's Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.

SPONSORED STORIES